Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer

Gynecologic Oncology

Volumn 131, Issue 3, 2013, Pages 535-540

  Hagemann, Andrea R ^a   Novetsky, Akiva P ^a   Zighelboim, Israel ^b   Gao, Feng ^a   Massad, L Stewart ^a   Thaker, Premal H ^a   Powell, Matthew A ^a   Mutch, David G ^a   Wright, Jason D ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Washington University School of Medicine and Siteman Cancer Center St Louis ^*  (United States)

Author keywords

Bevacizumab; Pemetrexed; Phase II; Recurrent ovarian cancer

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BEVACIZUMAB; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; INTESTINE PERFORATION; LEUKOPENIA; LUNG COMPLICATION; LUNG EMBOLISM; LYMPHATIC SYSTEM DISEASE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; UTERINE TUBE CARCINOMA; VASCULAR DISEASE;

BEVACIZUMAB; PEMETREXED; PHASE II; RECURRENT OVARIAN CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; GLUTAMATES; GUANINE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL RATE;

EID: 84888305195     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.09.032     Document Type: Article

References (26)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 1 Jan 2013 11 30
2. AC Society Cancer facts & figures Atlanta 2013
3. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 33 Nov 20 2007 5165 5171
4. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 26 Dec 29 2011 2484 2496
5. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 26 Dec 29 2011 2473 2483
6. C. Aghajanian, S.V. Blank, B.A. Goff, P.L. Judson, M.G. Teneriello, and A. Husain OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 17 Jun 10 2012 2039 2045
7. E.H.F. Pujade-Lauraine, B. Weber, A. Reuss, A. Poveda, and G. Kristensen AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) J Clin Oncol 30 2012 [(Supplementary). Abstract LBA5002]
8. C. Shih, V.J. Chen, L.S. Gossett, S.B. Gates, W.C. MacKellar, and L.L. Habeck LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Res 57 6 Mar 15 1997 1116 1123
9. K.D. Miller, L.I. Chap, F.A. Holmes, M.A. Cobleigh, P.K. Marcom, and L. Fehrenbacher Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 4 Feb 1 2005 792 799
10. D.S. Miller, J.A. Blessing, C.N. Krasner, R.S. Mannel, P. Hanjani, and M.L. Pearl Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group J Clin Oncol 27 16 Jun 1 2009 2686 2691
11. U.A. Matulonis, N.S. Horowitz, S.M. Campos, H. Lee, J. Lee, and C.N. Krasner Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer J Clin Oncol 26 35 Dec 10 2008 5761 5766
12. J. Sehouli, A.M. Alvarez, S. Manouchehrpour, P. Ghatage, C. Szczylik, and A. Zimmermann A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer Gynecol Oncol 124 2 Feb 2012 205 209
13. C.J. Sweeney, C.H. Takimoto, J.E. Latz, S.D. Baker, D.J. Murry, and J.H. Krull Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer Clin Cancer Res 12 2 Jan 15 2006 536 542
14. D.A. Rinaldi, J.G. Kuhn, H.A. Burris, F.A. Dorr, G. Rodriguez, and S.G. Eckhardt A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation Cancer Chemother Pharmacol 44 5 1999 372 380
15. G.J. Rustin, I. Vergote, E. Eisenhauer, E. Pujade-Lauraine, M. Quinn, and T. Thigpen Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG) Int J Gynecol Cancer 21 2 Feb 2011 419 423
16. N. Hanna, F.A. Shepherd, F.V. Fossella, J.R. Pereira, F. De Marinis, and J. von Pawel Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 9 May 1 2004 1589 1597
17. G.M. Dores, S.S. Devesa, R.E. Curtis, M.S. Linet, and L.M. Morton Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007 Blood 119 1 Jan 5 2012 34 43
18. A. Vay, S. Kumar, S. Seward, A. Semaan, C.A. Schiffer, and A.R. Munkarah Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis Gynecol Oncol 123 3 Dec 2011 456 460
19. L.A. Godley, and R.A. Larson Therapy-related myeloid leukemia Semin Oncol 35 4 Aug 2008 418 429
20. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 33 Nov 20 2007 5180 5186
21. A.A. Garcia, H. Hirte, G. Fleming, D. Yang, D.D. Tsao-Wei, and L. Roman Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 1 Jan 1 2008 76 82
22. K.F. McGonigle, H.G. Muntz, J. Vuky, P.J. Paley, D.S. Veljovich, and B.E. Greer Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study Cancer 117 16 Aug 15 2011 3731 3740
23. M.G. del Carmen, J. Micha, L. Small, D.G. Street, A. Londhe, and T. McGowan A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer Gynecol Oncol 126 3 Sep 2012 369 374
24. M.K. Parmar, J.A. Ledermann, N. Colombo, A. du Bois, J.F. Delaloye, and G.B. Kristensen Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 9375 Jun 21 2003 2099 2106
25. J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, and A.J. Lacave Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 29 Oct 10 2006 4699 4707
26. D.E. Cohn, K.H. Kim, K.E. Resnick, D.M. O'Malley, and J.M. Straughn Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis J Clin Oncol 29 10 Apr 1 2011 1247 1251